Evidence map›Paper›PMID 42446941›Full record

ArticleThe Journal of clinical investigation2026

A favorable follicular helper CD4+ T cell programming characterizes neutralization activity in chronic HIV infection.

Eirini Moysi, Ashish A Sharma, Sijy O'Dell, Spiros Georgakis, Perla Mariana Del Rio Estrada, Ghneim Khader, Alonso Arana, Fernanda Torres-Ruiz, Mauricio González Navarro, Yara Andrea Luna Villalobos and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Eirini MoysiTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Ashish A SharmaPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Sijy O'DellVirology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
Spiros GeorgakisDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Perla Mariana Del Rio EstradaPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Ghneim KhaderPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Alonso AranaPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Fernanda Torres-RuizCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Mexico City, Mexico.
Mauricio González NavarroCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Subdireccion de Otorrinolaringologia, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra," Mexico City, Mexico.
Yara Andrea Luna VillalobosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Mexico City, Mexico.
Santiago Avila RiosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Mexico City, Mexico.
Gustavo Reyes-TeranInstitutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud de México, Mexico City, Mexico.
Margaret H BeddallImmunoTechnology Section, Vaccine Research Center.
Sung Hee KoVirus Persistence and Dynamics Section, Vaccine Research Center, and.
Frida BelinkyVirus Persistence and Dynamics Section, Vaccine Research Center, and.
Michail OrfanakisDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Laurence de LevalDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Ana B EnriquezPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Clarisa M BucknerLaboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, USA.
Susan MoirLaboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, USA.
Helen LindsayBiomedical Data Science Center, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Raphael GottardoBiomedical Data Science Center, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Nicole Doria-RoseVirology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
Eli A BoritzVirus Persistence and Dynamics Section, Vaccine Research Center, and.
John R MascolaVirology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
Rafick-Pierre SekalyPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Richard A KoupTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Constantinos PetrovasTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.

Funding

Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
NIAID NIH HHS UM1 AI164561
6 · The paper itself

Abstract

A subset of people living with HIV (PLWH) can produce broadly neutralizing antibodies (bNAbs) against HIV, but the lymph node (LN) dynamics that promote the generation of these Abs are poorly understood. Here, we explored LN-associated histological, immunological, and virological determinants of bNAb generation in a cohort of antiretroviral therapy-naive PLWH. We found that participants who produce bNAbs, termed "neutralizers" (Ns), have a better-preserved LN-associated B cell follicle architecture than do PLWH who do not. The former was associated with a substantially higher in situ prevalence of B-cell lymphoma 6 (Bcl-6hi) follicular helper CD4+ T cells (Tfh), expressing a molecular program that favors their differentiation and stemness, and substantially reduced IL-10 follicular suppressor CD4+ T cells. Furthermore, our data reveal possible molecular targets mediating Tfh-B cell interactions in Ns. Together, we identify germinal center cellular and molecular signatures that could contribute to the development of bNAbs in PLWH.

Indexed as

Antibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsT Follicular Helper CellsT-Lymphocytes, Helper-InducerAdultB-LymphocytesCD4-Positive T-LymphocytesFemaleGerminal CenterHumansMaleProto-Oncogene Proteins c-bcl-6Antibodies, NeutralizingHIV AntibodiesProto-Oncogene Proteins c-bcl-6Adaptive immunityAIDS/HIVAIDS vaccineCellular immune responseImmunology

Identifiers

PMID42446941
PMCPMC13528940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.